<document>
 <table id="Table 2">
  <caption text="

   Membrane receptors present in LC neurons.
  
">
  </caption>
  <row row="0">
   <cell col-end="0" col-start="0" row-end="0" row-start="0" text="Neurotransmitter/neuromodulator">
   </cell>
   <cell col-end="1" col-start="1" row-end="0" row-start="0" text="Receptors in LC">
   </cell>
   <cell col-end="2" col-start="2" row-end="0" row-start="0" text="Effect on LC">
   </cell>
  </row>
  <row row="1">
   <cell col-end="0" col-start="0" row-end="1" row-start="1" text="Glutamate">
   </cell>
   <cell col-end="1" col-start="1" row-end="1" row-start="1" text="NMDA, AMPA">
   </cell>
   <cell col-end="2" col-start="2" row-end="1" row-start="1" text="Excitatory">
   </cell>
  </row>
  <row row="2">
   <cell col-end="0" col-start="0" row-end="2" row-start="2" text="GABA">
   </cell>
   <cell col-end="1" col-start="1" row-end="2" row-start="2" text="GABA
     
      A">
   </cell>
   <cell col-end="2" col-start="2" row-end="2" row-start="2" text="Inhibitory">
   </cell>
  </row>
  <row row="3">
   <cell col-end="0" col-start="0" row-end="3" row-start="3" text="NE">
   </cell>
   <cell col-end="1" col-start="1" row-end="3" row-start="3" text="Alpha-2">
   </cell>
   <cell col-end="2" col-start="2" row-end="3" row-start="3" text="Inhibitory">
   </cell>
  </row>
  <row row="4">
   <cell col-end="0" col-start="0" row-end="4" row-start="4" text="DA">
   </cell>
   <cell col-end="1" col-start="1" row-end="4" row-start="4" text="D
     
      1
     
     , D
     
      2">
   </cell>
   <cell col-end="2" col-start="2" row-end="4" row-start="4" text="Inhibitory">
   </cell>
  </row>
  <row row="5">
   <cell col-end="0" col-start="0" row-end="5" row-start="5" text="Acetylcholine">
   </cell>
   <cell col-end="1" col-start="1" row-end="5" row-start="5" text="Nicotinic">
   </cell>
   <cell col-end="2" col-start="2" row-end="5" row-start="5" text="Excitatory">
   </cell>
  </row>
  <row row="6">
   <cell col-end="0" col-start="0" row-end="6" row-start="6" text="Serotonin">
   </cell>
   <cell col-end="1" col-start="1" row-end="6" row-start="6" text="Serotonin
     
      1A">
   </cell>
   <cell col-end="2" col-start="2" row-end="6" row-start="6" text="Inhibitory">
   </cell>
  </row>
  <row row="7">
   <cell col-end="0" col-start="0" row-end="7" row-start="7" text="Orexin">
   </cell>
   <cell col-end="1" col-start="1" row-end="7" row-start="7" text="ORX-A">
   </cell>
   <cell col-end="2" col-start="2" row-end="7" row-start="7" text="Excitatory">
   </cell>
  </row>
  <row row="8">
   <cell col-end="0" col-start="0" row-end="8" row-start="8" text="Corticotrophin-releasing factor">
   </cell>
   <cell col-end="1" col-start="1" row-end="8" row-start="8" text="CRF-1">
   </cell>
   <cell col-end="2" col-start="2" row-end="8" row-start="8" text="Excitatory">
   </cell>
  </row>
  <row row="9">
   <cell col-end="0" col-start="0" row-end="9" row-start="9" text="Glucocorticoids">
   </cell>
   <cell col-end="1" col-start="1" row-end="9" row-start="9" text="GR, MR">
   </cell>
   <cell col-end="2" col-start="2" row-end="9" row-start="9" text="">
   </cell>
  </row>
  <row row="10">
   <cell col-end="0" col-start="0" row-end="10" row-start="10" text="Opioids">
   </cell>
   <cell col-end="1" col-start="1" row-end="10" row-start="10" text="Cannabinoid-1 Mu, Kappa">
   </cell>
   <cell col-end="2" col-start="2" row-end="10" row-start="10" text="Inhibitory">
   </cell>
  </row>
  <row row="11">
   <cell col-end="0" col-start="0" row-end="11" row-start="11" text="Substance P">
   </cell>
   <cell col-end="1" col-start="1" row-end="11" row-start="11" text="SP">
   </cell>
   <cell col-end="2" col-start="2" row-end="11" row-start="11" text="Excitatory">
   </cell>
  </row>
  <row row="12">
   <cell col-end="0" col-start="0" row-end="12" row-start="12" text="Melanin concentrating hormone">
   </cell>
   <cell col-end="1" col-start="1" row-end="12" row-start="12" text="MCH-1">
   </cell>
   <cell col-end="2" col-start="2" row-end="12" row-start="12" text="Inhibitory">
   </cell>
  </row>
  <row row="13">
   <cell col-end="0" col-start="0" row-end="13" row-start="13" text="Somatostatin">
   </cell>
   <cell col-end="1" col-start="1" row-end="13" row-start="13" text="SS-1−3">
   </cell>
   <cell col-end="2" col-start="2" row-end="13" row-start="13" text="Inhibitory">
   </cell>
  </row>
  <row row="14">
   <cell col-end="0" col-start="0" row-end="14" row-start="14" text="Neuropeptide Y">
   </cell>
   <cell col-end="1" col-start="1" row-end="14" row-start="14" text="NPY">
   </cell>
   <cell col-end="2" col-start="2" row-end="14" row-start="14" text="Inhibitory">
   </cell>
  </row>
  <statements>
   <statement id="0" text="Acetylcholine has Inhibitory effect on LC." type="">
   </statement>
   <statement id="2" text="Excitatory and Inhibitory are two types of effect on LC neurons." type="">
   </statement>
   <statement id="4" text="Glucocorticoids is the neurotransmitter which does not have effect on LC." type="">
   </statement>
   <statement id="5" text="In addition to detecting NE (through alpha-2 autoreceptors, which are the most abundant receptors within LC nuclei), they respond to several neurotransmitter and neuromodulators ( Table 2 )." type="">
   </statement>
   <statement id="7" text="LC neurons are the target of many neurochemical systems." type="">
   </statement>
   <statement id="8" text="NE is the only Neurotransmitter which has Alpha-2 receptor." type="">
   </statement>
   <statement id="9" text="Orexin, Neuropeptide Y has more than one receptor." type="">
   </statement>
   <statement id="10" text="Serotonin does not have any receptor." type="">
   </statement>
   <statement id="12" text="There are Five Neurotransmitters which has Excilatory Effect on LC." type="">
   </statement>
  </statements>
 </table>
 <table id="Table 3">
  <caption text="

   Experimental and theoretical progress on LC-NE system and proposed link to SCZ symptoms.
  
">
  </caption>
  <row row="0">
   <cell col-end="0" col-start="0" row-end="0" row-start="0" text="Advance of knowledge regarding LC-NE system">
   </cell>
   <cell col-end="1" col-start="1" row-end="0" row-start="0" text="Relation to schizophrenia">
   </cell>
  </row>
  <row row="1">
   <cell col-end="0" col-start="0" row-end="1" row-start="1" text="Specificity in LC projections to frontal regions, neuronal constitution and physiology (Section
     
      2.1.1
     
     )">
   </cell>
   <cell col-end="1" col-start="1" row-end="1" row-start="1" text="A disruption of the specific action that NE exerts on PFC circuits may underlie cognitive abnormalities observed in SCZ (Section
     
      3.2
     
     ).">
   </cell>
  </row>
  <row row="2">
   <cell col-end="0" col-start="0" row-end="2" row-start="2" text="LC activity coupled to brain oscillatory activity (Section
     
      2.1.1
     
     )">
   </cell>
   <cell col-end="1" col-start="1" row-end="2" row-start="2" text="Signatures of abnormal brain oscillatory activity are related to neurotransmitters and neuromodulators (Section
     
      3.3
     
     )">
   </cell>
  </row>
  <row row="3">
   <cell col-end="0" col-start="0" row-end="3" row-start="3" text="NE and DA co-release from LC terminals (Section
     
      2.1.4
     
     )">
   </cell>
   <cell col-end="1" col-start="1" row-end="3" row-start="3" text="NE/DA co-release may mediate the action of atypical pharmacological agents (Section
     
      3.5.2
     
     )">
   </cell>
  </row>
  <row row="4">
   <cell col-end="0" col-start="0" row-end="4" row-start="4" text="Signatures of LC activity during cognition in humans (Section
     
      2.2.3
     
     )">
   </cell>
   <cell col-end="1" col-start="1" row-end="4" row-start="4" text="Reduction of pupillometry and P3 signatures in SCZ during attention (Section
     
      3.3
     
     )">
   </cell>
  </row>
  <row row="5">
   <cell col-end="0" col-start="0" row-end="5" row-start="5" text="Role of LC in motivation to engage effort (Section
     
      2.2.3
     
     )">
   </cell>
   <cell col-end="1" col-start="1" row-end="5" row-start="5" text="Reduction of pupillometry signatures with increased effort (Section
     
      3.3
     
     )">
   </cell>
  </row>
  <row row="6">
   <cell col-end="0" col-start="0" row-end="6" row-start="6" text="GANE model of NE-glutamate interplay explains arousal-mediated effect of salient events (Section
     
      2.1.3
     
     )">
   </cell>
   <cell col-end="1" col-start="1" row-end="6" row-start="6" text="Altered function of molecules related to synaptic plasticity abnormally interact with neuromodulation in SCZ (Section
     
      3.2
     
     )">
   </cell>
  </row>
  <row row="7">
   <cell col-end="0" col-start="0" row-end="7" row-start="7" text="Network-reset and gain models of the effects of LC-NE system on switching and enhancement of brain networks’ activity (Section
     
      2.2.2
     
     )">
   </cell>
   <cell col-end="1" col-start="1" row-end="7" row-start="7" text="Lower signal-to-noise ratio of cortical circuits in SCZ (Section
     
      3.2
     
     )">
   </cell>
  </row>
  <row row="8">
   <cell col-end="0" col-start="0" row-end="8" row-start="8" text="Models of variability in LC recruitment and regulation of networks interaction explains traits such as working memory capacity (Section
     
      2.2.3
     
     )">
   </cell>
   <cell col-end="1" col-start="1" row-end="8" row-start="8" text="Triple-network model and reduced working memory capacity in SCZ (Section
     
      3.3
     
     )">
   </cell>
  </row>
  <row row="9">
   <cell col-end="0" col-start="0" row-end="9" row-start="9" text="Models of how LC-NE system controls the expression of brain states, i.e. stress (Section
     
      2.3.2
     
     )">
   </cell>
   <cell col-end="1" col-start="1" row-end="9" row-start="9" text="Susceptibility to stress is related to the symptomatology of SCZ (Sections
     
      3.3
     
     and
     
      3.4
     
     )">
   </cell>
  </row>
  <statements>
   <statement id="3" text="LC activity coupled to brain oscillatory activity (Section ) is the Advance of knowledge regarding LC-NE system ." type="">
   </statement>
   <statement id="6" text="Reduction of pupillometry and P3 signatures in SCZ during attention (Section ) is the Advance of knowledge regarding LC-NE system." type="">
   </statement>
   <statement id="8" text="Specificity in LC projections to frontal regions, neuronal constitution and physiology (Section ) it is Advance of knowledge regarding LC-NE system." type="">
   </statement>
  </statements>
 </table>
 <table id="Table 4">
  <caption text="

   Methodology to study the integrity of LC-NE system in humans.
  
">
  </caption>
  <row row="0">
   <cell col-end="0" col-start="0" row-end="0" row-start="0" text="Method">
   </cell>
   <cell col-end="1" col-start="1" row-end="0" row-start="0" text="Relation to LC-NE system">
   </cell>
   <cell col-end="2" col-start="2" row-end="0" row-start="0" text="Advantages">
   </cell>
   <cell col-end="3" col-start="3" row-end="0" row-start="0" text="Limitations">
   </cell>
  </row>
  <row row="1">
   <cell col-end="0" col-start="0" row-end="1" row-start="1" text="Pharmacological challenge (e.g. atomoxetine)">
   </cell>
   <cell col-end="1" col-start="1" row-end="1" row-start="1" text="Changes in synaptic concentrations of NE mimic the effects of elevated/ reduced NE release by LC.">
   </cell>
   <cell col-end="2" col-start="2" row-end="1" row-start="1" text="Allows within-subject comparison of behavior and physiology (i.e. normal vs. elevated NE levels).">
   </cell>
   <cell col-end="3" col-start="3" row-end="1" row-start="1" text="Pharmacological agents are rarely specific of one neuromodulatory system and likely interact with other systems; each individual may have different responsivity; invasive.">
   </cell>
  </row>
  <row row="2">
   <cell col-end="0" col-start="0" row-end="2" row-start="2" text="PET">
   </cell>
   <cell col-end="1" col-start="1" row-end="2" row-start="2" text="NE transporter availability reflects functionality of LC projections.">
   </cell>
   <cell col-end="2" col-start="2" row-end="2" row-start="2" text="Allows for direct molecular quantification.">
   </cell>
   <cell col-end="3" col-start="3" row-end="2" row-start="2" text="Very low temporal resolution; invasive.">
   </cell>
  </row>
  <row row="3">
   <cell col-end="0" col-start="0" row-end="3" row-start="3" text="Pupillometry">
   </cell>
   <cell col-end="1" col-start="1" row-end="3" row-start="3" text="Non-reflexive pupil dilation accompanies LC phasic activation and tracks changes in tonic LC firing.">
   </cell>
   <cell col-end="2" col-start="2" row-end="3" row-start="3" text="Relatively high temporal resolution to study task-evoked LC activity with low budget; non-invasive.">
   </cell>
   <cell col-end="3" col-start="3" row-end="3" row-start="3" text="Constitutes an indirect measurement of LC activity; other neuromodulators may contribute to changes in pupil size.">
   </cell>
  </row>
  <row row="4">
   <cell col-end="0" col-start="0" row-end="4" row-start="4" text="Neuromelanin-sensitive MRI">
   </cell>
   <cell col-end="1" col-start="1" row-end="4" row-start="4" text="LC is rich in neuromelanin, a molecule that is paramagnetic and can be detected through MRI.">
   </cell>
   <cell col-end="2" col-start="2" row-end="4" row-start="4" text="Allows the highest precision in LC localization in humans in vivo; non-invasive.">
   </cell>
   <cell col-end="3" col-start="3" row-end="4" row-start="4" text="Does not provide information about LC function; intensity in LC may vary with age.">
   </cell>
  </row>
  <row row="5">
   <cell col-end="0" col-start="0" row-end="5" row-start="5" text="fMRI">
   </cell>
   <cell col-end="1" col-start="1" row-end="5" row-start="5" text="Blood oxygen level dependent (BOLD) changes in LC reflect the level of neuronal activation in the nuclei.">
   </cell>
   <cell col-end="2" col-start="2" row-end="5" row-start="5" text="Allows measuring task-related and resting state changes of activity with relatively high spatial resolution; non-invasive.">
   </cell>
   <cell col-end="3" col-start="3" row-end="5" row-start="5" text="Many sources of artifacts affect the quality of the measurements, i.e. head movement and confounds from cerebro-spinal fluid vicinity; the small size of LC may also provide a low signal-to-noise ratio; requires specific brainstem co-registration steps.">
   </cell>
  </row>
  <row row="6">
   <cell col-end="0" col-start="0" row-end="6" row-start="6" text="ERP (P300)">
   </cell>
   <cell col-end="1" col-start="1" row-end="6" row-start="6" text="P3 indexes phasic LC response.">
   </cell>
   <cell col-end="2" col-start="2" row-end="6" row-start="6" text="Allows high temporal resolution of a relatively well characterized component; non-invasive.">
   </cell>
   <cell col-end="3" col-start="3" row-end="6" row-start="6" text="LC contributes only in part to the component.">
   </cell>
  </row>
  <statements>
   <statement id="0" text="Each method has its own limitations." type="">
   </statement>
   <statement id="1" text="Every method is having same advantages." type="">
   </statement>
   <statement id="2" text="Molecular quantification is an advantage of fMRI method." type="">
   </statement>
   <statement id="3" text="Molecular quantification is an advantage of PET method." type="">
   </statement>
   <statement id="4" text="PET method does not have any limitations." type="">
   </statement>
   <statement id="5" text="PET method has only one advantage." type="">
   </statement>
   <statement id="7" text="The inclusion of neuromodulatory markers, such as ocular measures ( Table 4 ), will allow inspecting the neurobiological factors contributing to inter-individual differences in SCZ ( Diminich and Goff, 2016 )." type="">
   </statement>
   <statement id="8" text="There are six methodology is given in the table." type="">
   </statement>
   <statement id="9" text="There are ten methodology is given in the table." type="">
   </statement>
  </statements>
 </table>
</document>